Drugs

Article	Citations
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	417
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	395
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	296
Bimekizumab for the Treatment of Psoriasis	282
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	218
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	190
Targeting DNA Damage Response Deficiency in Thoracic Cancers	169
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	161
Teclistamab: First Approval	136
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	135
Spesolimab for the Treatment of Generalized Pustular Psoriasis	117
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	113
Aprocitentan: First Approval	107
Eftrenonacog Alfa: A Review in Haemophilia B	107
Vorasidenib: First Approval	105
New Therapies on the Horizon for Primary Biliary Cholangitis	103
Epcoritamab: First Approval	100
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	98
Finerenone: First Approval	96
Upacicalcet: First Approval	94
Lenacapavir: First Approval	93
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine	92
Dasiglucagon: First Approval	92
Cosibelimab: First Approval	91
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer	89

Drugs in Development to Manage Acute Pain	88
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies	87
Dostarlimab: First Approval	86
Olipudase Alfa: First Approval	84
Atogepant: First Approval	84
Androgenetic Alopecia: Therapy Update	84
Repotrectinib: First Approval	83
Mosunetuzumab: First Approval	82
Danicopan: First Approval	82
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?	78
Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia	78
Olverembatinib: First Approval	76
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	76
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	75
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection	75
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids	73
Cancer Pain Treatment Strategies in Patients with Cancer	72
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	72
Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections	70
Correction to: Prevention and Treatment of Monkeypox	69
Dorzagliatin: First Approval	69
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	69
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology	69
Correction to: Tapinarof Cream 1%: First Approval	68
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough	67
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer	66
Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A	66
Pozelimab: First Approval	66
The Place of Cannabinoids in the Treatment of Gynecological Pain	66
Sunvozertinib: First Approval	66
Tovorafenib: First Approval	64
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned	64
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis	63
Correction to: Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis	62
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab	62
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options	62
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study	61
Gepirone Extended-Release: First Approval	61
Birch Bark Extract: A Review in Epidermolysis Bullosa	60
Correction to: Concizumab: First Approval	60
Ponesimod: First Approval	60
Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence	59
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy	59
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?	58
Asciminib: First Approval	57
Aumolertinib: A Review in Non-Small Cell Lung Cancer	57
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’	57
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology	56
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses	55
Givinostat: First Approval	54

Ozoralizumab: First Approval	53
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond	53
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials	53
Tirzepatide: A Review in Type 2 Diabetes	52
Correction to: Remdesivir: A Review in COVID-19	51
Targeting Sphingosine-1-Phosphate Signaling in Immune-Mediated Diseases: Beyond Multiple Sclerosis	50
Catumaxomab: First Approval	49
Disitamab Vedotin: First Approval	49
Correction to: Sotorasib: First Approval	49
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults	49
Correction to: Efmoroctocog Alfa: A Review in Haemophilia A	49
Correction: Teprotumumab: A Review in Thyroid Eye Disease	48
Ensitrelvir Fumaric Acid: First Approval	48
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy	48
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study	47
Avacincaptad Pegol: First Approval	47
Fezolinetant: First Approval	47
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes	46
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets	46
Tisotumab Vedotin: First Approval	46
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	45
Futibatinib: First Approval	45
Zastaprazan: First Approval	45
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	45
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	44
Could Sodium/Glucose Co-Transporter-2 Inhibitors Have Antiarrhythmic Potential in Atrial Fibrillation? Literature Review and Future Considerations	43
Eye Involvement and Management in Inherited Epidermolysis Bullosa	43
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis	43
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	43
Correction: Iptacopan: First Approval	42
Lotilaner Ophthalmic Solution 0.25%: First Approval	41
Beremagene Geperpavec: First Approval	41
Gastrointestinal Dysfunction in Parkinson’s Disease	41
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	41
Savolitinib: First Approval	40
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	40
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	40
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	40
Imeglimin Hydrochloride: First Approval	39
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	39
Imetelstat: First Approval	39
Tebentafusp: First Approval	39
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin	39
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management	38
Acknowledgement to Referees	38
Correction to: Pharmacological Approaches to Managing Violence and Aggression in Prison Populations: Clinical and Ethical Issues	37
Revumenib: First Approval	36
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	36
Nogapendekin alfa Inbakicept: First Approval	36
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid	36
Retifanlimab: First Approval	36
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	35
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”	34
Epidemiology, Treatments, and Vaccine Development for Antimicrobial-Resistant Neisseria gonorrhoeae: Current Strategies and Future Directions	34
Crinecerfont: First Approval	34
Mavorixafor: First Approval	33
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	33
Diagnosis and Treatment of AL Amyloidosis	33
Avatrombopag: A Review in Thrombocytopenia	33
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials	33
The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update	32
Donafenib: First Approval	32
Correction to: Sparsentan: First Approval	32
Antibacterials with Novel Chemical Scaffolds in Clinical Development	31
Correction to: Abrocitinib: First Approval	31
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial	30
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer	30
Rationale and Clinical Use of Bronchodilators in Adults with Bronchiectasis	30
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy	30
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy	30
Correction: Zastaprazan: First Approval	29
Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care	29
Zolbetuximab: First Approval	29
Correction to: Spesolimab: First Approval	29
Methadone for Cancer Pain Management in Children: A Review of Literature	29
Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study	29
Insights Into the Results of Sotagliflozin Cardiovascular Outcome Trials: Is Dual Inhibition the Cherry on the Cake of Cardiorenal Protection?	28
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval	28
Keverprazan Hydrochloride: First Approval	28
Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”	28

Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study	27
Ravulizumab: A Review in Generalised Myasthenia Gravis	27
Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective	27
Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients	27
Remdesivir: A Review in COVID-19	27
Daridorexant: First Approval	27
Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy	26
Spesolimab: First Approval	26
Odevixibat: First Approval	26
Abrocitinib: First Approval	26
Novel Drug Therapeutics in Celiac Disease: A Pipeline Review	26
Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management	26